OSCR
Oscar Health, Inc.
OSCR has a slight edge over TECH overall, supported by stronger valuation and stronger fundamentals.
TECH
Bio-Techne Corporation
TECH has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TECH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
TECH's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over TECH in the historical PE scenario, which offers more potential upside but is not a forecast.
TECH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 34x | $72.84 | — |
| Cheap | 46x | $50.62 | -30% |
| Fair | 63x | $69.08 | -5.2% |
| Current | 66x | $72.84 | — |
| Expensive | 104x | $114 | +57% |
Historical ranges are pointers, not guarantees.
TECH's PE is in its fair range at 66x. If earnings grow as analysts expect, today's price would be 34x next year's earnings, in its cheap range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TECH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for TECH, with profitability improving.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TECH on earnings, with more consistent year-over-year improvement.
TECH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.12 | +93% |
| Q3 2026 | $1.10 | +124% |
| Q2 2026 | $1.16 | +152% |
| Q1 2026 | $0.69 | -17% |
| Q4 2025 | $0.51 | -49% |
| Q3 2025 | $0.49 | -48% |
| Q2 2025 | $0.46 | -56% |
| Q1 2025 | $0.83 | -34% |
| Q4 2024 | $1.00 | -28% |
TECH's earnings per share have fallen from their peak: $1.10 over the past year, against $1.79 in late 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TECH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
TECH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $299.7M | +4.6% |
| Q2 2026 | $321.2M | +1.3% |
| Q1 2026 | $311.4M | -1.5% |
| Q4 2025 | $295.9M | -0.4% |
| Q3 2025 | $286.6M | -1% |
| Q2 2025 | $317M | +3.5% |
| Q1 2025 | $316.2M | +4.2% |
| Q4 2024 | $297M | +9% |
TECH's revenue grew through 2023 and has held roughly level since: $300M last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | -4.4 points |
| Q2 2026 | 23% | +31 points |
| Q1 2026 | 24% | +12 points |
| Q4 2025 | 18% | +2.4 points |
| Q3 2025 | 17% | +2.8 points |
| Q2 2025 | -7.5% | -23 points |
| Q1 2025 | 12% | -9.8 points |
| Q4 2024 | 16% | +2 points |
TECH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TECH on cash flow, with more consistent year-over-year improvement.
TECH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $67.2M | +202% |
| Q2 2026 | $86.9M | -6.8% |
| Q1 2026 | $77.6M | +150% |
| Q4 2025 | $76.5M | -1.3% |
| Q3 2025 | $22.2M | -59% |
| Q2 2025 | $93.3M | +62% |
| Q1 2025 | $31M | -52% |
| Q4 2024 | $77.5M | +14% |
TECH's free cash flow has been positive every quarter for six years: $308M over the past year, up 38% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TECH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +919K shares |
| 1 year | +1% | +1.6M shares |
| 3 years | -2.5% | -4M shares |
| 5 years | -4.1% | -6.7M shares |
| Available history | -0.2% | -272K shares |
TECH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $41.7M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $24,000 |
| Q2 2025 | $100.1M |
| Q1 2025 | $100M |
| Q2 2024 | — |
| Q1 2024 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over TECH on leverage, with a lower net debt burden relative to earnings.
TECH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.4x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.4x | Very low |
TECH has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TECH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.9 | Neutral |
| Stochastic | 94.2 | Overbought |
TECH's weekly RSI is 66 (neutral) and its Stochastic is 94 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over TECH on valuation relative to its sector.
TECH PE vs Healthcare Sector
| Metric | TECH | Sector median | Relative |
|---|---|---|---|
| PE | 66x | 26x | 156% above |
| PE % | 55 | 29 | 26 pts above |
TECH is trading at 66x earnings, a 156% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
TECH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.6 | 0.3% above |
| 20 week MA | $72.3 | 0.8% above |
| 50 week MA | $63.3 | 15% above |
| 100 week MA | $61.0 | 20% above |
| 200 week MA | $67.7 | 7.5% above |
TECH has climbed back above all five of its weekly moving averages, and it's now 7.5% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TECH on returns for 2026, with the stronger performance.
TECH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.6 | $80.4 | +47% |
| 2021 | $80.4 | $123.7 | +54% |
| 2022 | $123.7 | $82.7 | -33% |
| 2023 | $82.7 | $77.2 | -6.7% |
| 2024 | $77.2 | $73.0 | -5.4% |
| 2025 | $73.0 | $59.2 | -19% |
| 2026 YTD | $59.2 | $72.8 | +23% |
TECH has finished four years in a row lower, and it's up 23% so far in 2026.